| Reaction Details |
|---|
 | Report a problem with these data |
| Target | Aldo-keto reductase family 1 member C1 |
|---|
| Ligand | BDBM50427627 |
|---|
| Substrate/Competitor | n/a |
|---|
| Meas. Tech. | Inhibition Assay |
|---|
| IC50 | >100±n/a nM |
|---|
| Citation |  Marnett, LJ; Liedtke, AJ; Penning, TM; Adeniji, AO; Byrns, MC Indomethacin analogs for the treatment of castrate-resistant prostate cancer US Patent US9346803 Publication Date 5/24/2016 |
|---|
| More Info.: | Get all data from this article, Assay Method |
|---|
| |
| Aldo-keto reductase family 1 member C1 |
|---|
| Name: | Aldo-keto reductase family 1 member C1 |
|---|
| Synonyms: | 20-alpha-HSD | 20-alpha-Hydroxysteroid Dehydrogenase (AKR1C1) | AK1C1_HUMAN | AKR1C1 | Aldo-keto reductase family 1 member C1 (AK1C1) | Aldo-keto reductase family 1 member C1 (AK1C1a) | Aldo-keto reductase family 1 member C1 (AKR1C1) | Chlordecone reductase homolog HAKRC | DDH | DDH1 | High-affinity hepatic bile acid-binding protein | Trans-1,2-dihydrobenzene-1,2-diol dehydrogenase |
|---|
| Type: | Enzyme |
|---|
| Mol. Mass.: | 36793.97 |
|---|
| Organism: | Homo sapiens (Human) |
|---|
| Description: | Recombinant AKR1C1 enzyme was expressed in E. coli. |
|---|
| Residue: | 323 |
|---|
| Sequence: | MDSKYQCVKLNDGHFMPVLGFGTYAPAEVPKSKALEATKLAIEAGFRHIDSAHLYNNEEQ
VGLAIRSKIADGSVKREDIFYTSKLWCNSHRPELVRPALERSLKNLQLDYVDLYLIHFPV
SVKPGEEVIPKDENGKILFDTVDLCATWEAVEKCKDAGLAKSIGVSNFNRRQLEMILNKP
GLKYKPVCNQVECHPYFNQRKLLDFCKSKDIVLVAYSALGSHREEPWVDPNSPVLLEDPV
LCALAKKHKRTPALIALRYQLQRGVVVLAKSYNEQRIRQNVQVFEFQLTSEEMKAIDGLN
RNVRYLTLDIFAGPPNYPFSDEY
|
|
|
|---|
| BDBM50427627 |
|---|
| n/a |
|---|
| Name | BDBM50427627 |
|---|
| Synonyms: | CHEMBL2323474 | US9346803, Table 2, Compound 9: 2-{5-methoxy-2-methyl-1-[4-(trifluoromethyl)benzoyl]-1H-indol-3-yl}acetic acid |
|---|
| Type | Small organic molecule |
|---|
| Emp. Form. | C20H16F3NO4 |
|---|
| Mol. Mass. | 391.3405 |
|---|
| SMILES | COc1ccc2n(C(=O)c3ccc(cc3)C(F)(F)F)c(C)c(CC(O)=O)c2c1 |
|---|
| Structure | 
|
|---|
Search and Browse
